Abdul Fattah Memon, Fahad Feroze Shaikh, Abdul Qadeem Soomro.
Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion with Intravitreal Bevacizumab.
Ophthalmol Update Jan ;14(1):67-70.

Purpose: To determine the anatomical and visual outcomes after intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Study Design: Prospective, interventional case series. Patients & Methods: This study was conducted from January 2015 to September 2015 at Al-Ibrahim Eye Hospital, Karachi. Selected patients having ME secondary to BRVO were given IVB 1.25mg at monthly intervals until the ME subsided. The patients were followed up for a minimum of 3 months. Complete ophthalmic examination and measurement of central macular thickness (CMT) by optical coherence tomography (OCT) were performed at baseline and follow-up visits. Results: Forty-five eyes of 43 patients were included in the study. The mean CMT at baseline was 578.3 � 156.1 ?m, and it significantly improved at each follow-up, with a CMT of 281.2 � 133.2 ?m at the last follow-up (p < 0.001). The mean bestcorrected visual acuity (BCVA) at baseline was 0.79 � 0.49, and it significantly improved at each follow-up, with a BCVA of 0.42 � 0.30 at the last follow-up (p < 0.001). The BCVA was improved in 38 (84%) eyes of the eyes. The average number of intravitreal bevacizumab injections was 3.8 (range= 2 - 7 injections). Recurrent ME occurred in 15 (33.3%) of eyes. Conclusion: Intravitreal bevacizumab is an effective agent for the treatment of BRVO. It reduces ME, resulting in improvement in visual acuity.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com